- Home
- NAAS vs MYNZ Comparison
NAAS vs MYNZ Comparison
Compare NAAS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- MYNZ
- Stock Information
- Founded
- NAAS 2019
- MYNZ 2021
- Country
- NAAS China
- MYNZ Germany
- Employees
- NAAS N/A
- MYNZ N/A
- Industry
- NAAS Other Specialty Stores
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- MYNZ Health Care
- Exchange
- NAAS Nasdaq
- MYNZ Nasdaq
- Market Cap
- NAAS 8.3M
- MYNZ 7.9M
- IPO Year
- NAAS 2017
- MYNZ 2021
- Fundamental
- Price
- NAAS $2.75
- MYNZ $1.77
- Analyst Decision
- NAAS
- MYNZ Buy
- Analyst Count
- NAAS 0
- MYNZ 2
- Target Price
- NAAS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- NAAS 229.9K
- MYNZ 180.5K
- Earning Date
- NAAS 08-26-2025
- MYNZ 08-26-2025
- Dividend Yield
- NAAS N/A
- MYNZ N/A
- EPS Growth
- NAAS N/A
- MYNZ N/A
- EPS
- NAAS N/A
- MYNZ N/A
- Revenue
- NAAS $27,534,354.00
- MYNZ $893,991.00
- Revenue This Year
- NAAS $378.49
- MYNZ $26.06
- Revenue Next Year
- NAAS N/A
- MYNZ $4.97
- P/E Ratio
- NAAS N/A
- MYNZ N/A
- Revenue Growth
- NAAS N/A
- MYNZ N/A
- 52 Week Low
- NAAS $1.96
- MYNZ $1.30
- 52 Week High
- NAAS $84.80
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- NAAS 48.66
- MYNZ 53.56
- Support Level
- NAAS $2.18
- MYNZ $1.41
- Resistance Level
- NAAS $2.90
- MYNZ $1.76
- Average True Range (ATR)
- NAAS 0.42
- MYNZ 0.16
- MACD
- NAAS 0.07
- MYNZ 0.02
- Stochastic Oscillator
- NAAS 57.48
- MYNZ 68.12
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.